Tentative signs of rocket firing, page-84

First 84 Last

Share
Profile

Follow
Melrosian

2,018 Posts.

08/02/17

23:13

Post #: 22471331
Share

Originally posted by Melrosian ↑

Kamikaze

I have said this before but post purchase of PSD from QPP I looked at the gearing ratio of SGH and it was glaringly obvious that :

1. SGH wouldnt fit with investing institutions and they would run for cover.
2. As they and those "obliged" to support the placing ran for cover they would if they could short.
3. AG wouldnt say it was accretive unless that was so - but probably not immediately.
4. £90 M advertising spend , new Manchester office move and new broom elements made gearing worse.
5. there would be a shorters fest.

Well right so far and now , relative to expected future profits the SGH shares are astonishingly cheap.

What next? Any large company can cut it least profitable trading and that is cash generative. The 53000 hearing loss cases would absorb cash short term but it was clear , given the structure of the profits split, that both sides expected clarity on outcomes within 2 years. Here we are in 2017 and I expect evidence on likely outcomes soon. Even if there is a poor return on NIHL - they are likely to generate 8 and possibly 9 figure net cash in 2017/18. The Escrow dispute could bear fruit ( no idea).
My calculations suggest operations will generate $60 M pa cash +ve on an ongoing basis and I am hoping for one off $60-120M cash in 2017. If at the disappointing end of my leverage sensitivity calculations ( which rely on a a lot of guesswork ) I think SGH should look for $100-200M new dilutive equity this time next year.

Even if the 2017 outcomes prove to be disappointing - the current SP is ridiculous. It should be over a dollar ......and I shall eat my hat if it is not so in feb 2017. Add a bit of good news and double that.

Yup. I am a relaxed investor in a fairly dull professional services business. Divy in 2018 please.
A return to last divy level ......33% divy returns would do nicely. Clear recovery and Redde plc shows us that a valuation of 20 times profits in future is possible. Geometric progression is lovely...add a modicum of growth ......then Yee Haaa!

Now it is valued at less than 1 times future profits. The market always tends to overshoot both ways.
DAFT!

Mel

Expand

Eating my hat - should be 2018 over $
Sorry
Mel

SGH Price at posting: 25.5¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 541 more messages in this thread...

First 84 Last

Add SGH (ASX) to my watchlist

Tentative signs of rocket firing, page-84

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News